Table 6.4.
Selected trials on efficacy of Favipiravir against COVID-19 infection.
| Trial registration code | Trial type | Total number of patients enrolled | Objective/Outcome | References |
|---|---|---|---|---|
| ChiCTR200030254 | Randomized control trial | 240 120—Favipiravir 120—Arbidol |
Comparison of safety and efficacy of Arbidol and Favipiravir in treatment of patients with COVID-19 infection. Higher recovery rate in patients treated with Favipiravir along with faster relief from cough and pyrexia. |
[99] |
| ChiCTR2000030113 | Interventional study | 15—Control group Intervention: Ritonavir 15—Experimental group Intervention: Favipiravir |
Observing the safety and effectiveness of Favipiravir for treating novel coronavirus–related pneumonia with poorly responsive ritonavir. | [100] |
| ChiCTR2000029600 | Interventional study |
30—Group A Intervention: Alpha-interferon atomization 30—Group B Intervention: Combination of lopinavir/ritonavir along with Alpha-interferon 30—Group C Intervention: Favipiravir + alpha-interferon atomization |
Monitoring safety and effectiveness of Favipiravir for treatment of SARS-CoV-2 infection associated pneumonia. | [101] |
| ChiCTR2000029544 | Interventional study |
10—Group 1 Intervention: Current antiviral treatment + baloxavir marboxil tablets 10—Group 2 Intervention: Current antiviral treatment + Favipiravir tablets 10—Group 3 Intervention: Current antiviral treatment |
Evaluating the effectiveness and safety of combination of baloxavir marboxil or Fabiravir dipivoxil for treating patients having SARS-CoV-2 infection. | [102] |
| ChiCTR2000029548 | Interventional study |
10—Group A Intervention: 80 mg of baloxavir marboxil on first day, 80 mg on fourth day, and 80 mg on seventh day if required. Not to be administered more than three times in total. 10—Group B 600 mg of Favipiravir, three times a day along with 1600 mg first loading up to 14 days. 10—Group C Intervention: 200 mg of lopinavir and 50 mg of ritonavir two times a day for 14 days |
Evaluating the effectiveness and safety of baloxavir marboxil, lopinavir/ritonavir, and Favipiravir for treating patients having SARS-CoV-2 infection. | [103] |
| ChiCTR2000030894 | Interventional study |
90—Group 1 Intervention: Combination of Favipiravir with tocilizumab 30—Group 2 Intervention: Favipiravir 30—Group 3 Intervention: Tocilizumab |
Evaluating the effectiveness and safety of Favipiravir in combination with tocilizumab for treating patients having SARS-CoV-2 infection. | [104]. |